Comparison of Complement Dependent Lytic, Hemagglutination Inhibition and Microneutralization Antibody Responses in Influenza Vaccinated Individuals

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2012 Aug 17

PMID 22894961

Citations 11

Authors

Mary Dawn T Co

John Cruz

Akira Takeda

Francis A Ennis

Masanori Terajima

Affiliations

Soon will be listed here.

Abstract

Virus specific, non-neutralizing antibodies such as complement dependent lytic (CDL) antibodies may reduce morbidity following infection through the clearance of infectious virus particles and infected cells. We examined hemagglutination inhibition (HAI), microneutralization (MN) and CDL antibody titers to influenza A H1 and H3 virus strains in 23 healthy young adults who received the 2005-2006 trivalent inactivated influenza vaccine. Post vaccination, we detected statistically significant increases in MN and CDL antibodies but not in HAI antibodies. Statistically significantly higher fold increases in CDL antibodies post vaccination were seen compared with MN and HAI antibodies post vaccination. However, the overall fold increases were modest, likely related to the fact that most of the subjects had received influenza vaccination previously. This study showed that influenza vaccination is not only capable of increasing the level of antibodies that neutralize virus but also antibodies that can cause lysis of infected cells. The biological significance of these CDL antibodies merits further investigation in clinical studies.

Citing Articles

Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial.

Boudreau C, Burke 4th J, Shuey K, Wolf C, Katz J, Tielsch J Cell Rep. 2022; 38(6):110337.

PMID: 35139373 PMC: 9026287. DOI: 10.1016/j.celrep.2022.110337.

Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system.

Friel D, Co M, Ollinger T, Salaun B, Schuind A, Li P Influenza Other Respir Viruses. 2020; 15(1):110-120.

PMID: 32889792 PMC: 7767944. DOI: 10.1111/irv.12780.

Antivirals Targeting the Neuraminidase.

Gubareva L, Mohan T Cold Spring Harb Perspect Med. 2020; 12(1).

PMID: 32152244 PMC: 8725622. DOI: 10.1101/cshperspect.a038455.

Non-neutralizing Antibodies Directed at Conservative Influenza Antigens.

Sedova E, Scherbinin D, Lysenko A, Alekseeva S, Artemova E, Shmarov M Acta Naturae. 2020; 11(4):22-32.

PMID: 31993232 PMC: 6977952. DOI: 10.32607/20758251-2019-11-4-22-32.

Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.

Piepenbrink M, Nogales A, Basu M, Fucile C, Liesveld J, Keefer M mBio. 2019; 10(2).

PMID: 30862743 PMC: 6414695. DOI: 10.1128/mBio.00066-19.

References

Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W . Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology. 2006; 352(2):418-26. DOI: 10.1016/j.virol.2006.05.008. View

Quinnan G, Ennis F, Tuazon C, Wells M, Butchko G, Armstrong R . Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun. 1980; 30(2):362-9. PMC: 551319. DOI: 10.1128/iai.30.2.362-369.1980. View

Co M, Orphin L, Cruz J, Pazoles P, Rothman A, Ennis F . Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine. 2008; 26(16):1990-8. PMC: 2440689. DOI: 10.1016/j.vaccine.2008.02.024. View

HICKS J, Klutch M, Albrecht P, Frank M . Analysis of complement-dependent antibody-mediated lysis of target cells acutely infected with measles. J Immunol. 1976; 117(1):208-15. View

Hirota Y, Kaji M, Ide S, Goto S, Oka T . The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age. Vaccine. 1996; 14(17-18):1597-602. DOI: 10.1016/s0264-410x(96)00153-3. View

Wrammert J, Koutsonanos D, Li G, Edupuganti S, Sui J, Morrissey M . Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011; 208(1):181-93. PMC: 3023136. DOI: 10.1084/jem.20101352. View

Gardner E, Bernstein E, Dran S, Munk G, Gross P, Abrutyn E . Characterization of antibody responses to annual influenza vaccination over four years in a healthy elderly population. Vaccine. 2001; 19(32):4610-7. DOI: 10.1016/s0264-410x(01)00246-8. View

Qu Z, Liang X, Liu Y, Du J, Liu S, Sun W . Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59. Mol Immunol. 2009; 47(2-3):283-9. DOI: 10.1016/j.molimm.2009.09.022. View

Natsume A, Niwa R, Satoh M . Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther. 2009; 3:7-16. PMC: 2769226. View

10.

Huber M, Trkola A . Humoral immunity to HIV-1: neutralization and beyond. J Intern Med. 2007; 262(1):5-25. DOI: 10.1111/j.1365-2796.2007.01819.x. View

11.

HICKS J, Ennis F, Kim E, Verbonitz M . The importance of an intact complement pathway in recovery from a primary viral infection: influenza in decomplemented and in C5-deficient mice. J Immunol. 1978; 121(4):1437-45. View

12.

Verbonitz M, Ennis F, HICKS J, Albrecht P . Hemagglutinin-specific complement-dependent cytolytic antibody response to influenza infection. J Exp Med. 1978; 147(1):265-70. PMC: 2184088. DOI: 10.1084/jem.147.1.265. View

13.

Terajima M, Cruz J, Co M, Lee J, Kaur K, Wrammert J . Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol. 2011; 85(24):13463-7. PMC: 3233150. DOI: 10.1128/JVI.05193-11. View

14.

Reading P, Hartley C, Ezekowitz R, Anders E . A serum mannose-binding lectin mediates complement-dependent lysis of influenza virus-infected cells. Biochem Biophys Res Commun. 1995; 217(3):1128-36. DOI: 10.1006/bbrc.1995.2886. View

15.

Szretter K, Balish A, Katz J . Influenza: propagation, quantification, and storage. Curr Protoc Microbiol. 2008; Chapter 15:Unit 15G.1. DOI: 10.1002/0471729256.mc15g01s3. View

16.

Papenburg J, Baz M, Hamelin M, Rheaume C, Carbonneau J, Ouakki M . Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clin Vaccine Immunol. 2011; 18(3):520-2. PMC: 3067392. DOI: 10.1128/CVI.00449-10. View

17.

Wrammert J, Smith K, Miller J, Langley W, Kokko K, Larsen C . Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008; 453(7195):667-71. PMC: 2515609. DOI: 10.1038/nature06890. View

18.

Sissons J, Schreiber R, Perrin L, Cooper N, MULLER-EBERHARD H, Oldstone M . Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody. J Exp Med. 1979; 150(3):445-54. PMC: 2185658. DOI: 10.1084/jem.150.3.445. View

19.

de Jong J, Palache A, Beyer W, Rimmelzwaan G, Boon A, Osterhaus A . Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2004; 115:63-73. View

20.

Beyer W, Palache A, Luchters G, Nauta J, Osterhaus A . Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res. 2004; 103(1-2):125-32. DOI: 10.1016/j.virusres.2004.02.024. View